mesothelioma treatment

Genentech Halts Avastin Approval Filing for Mesothelioma

In 2015, data was presented at the American Society of Clinical Oncology (ASCO) Annual Meeting from a Phase III French study that demonstrated improved survival rates for patients who received bevacizumab (Avastin® Genentech, Inc.) in addition to the standard chemotherapy regimen of pemetrexed/cisplatin.
The outcome of the study prompted the independent French cooperative group and Genentech […]



Updates in Mesothelioma Research from ASCO 2017

The American Society of Clinical Oncology (ASCO) held its Annual Meeting on June 2-6, 2017 in Chicago. The Meso Foundation’s CEO, Melinda Kotzian, and Director of Research and Medical Outreach, Gleneara Bates, MS, MSW, PhD (c), had the opportunity to attend the conference and hear the latest news reported in mesothelioma research.
Hedy Lee Kindler, MD, […]


Results Show Encouraging Survival Data: Nintedanib for Mesothelioma

On June 5, Anna Nowak, MD, PhD, of the University of Western Australia and member of the Meso Foundation’s Science Advisory Board, presented phase II results from LUME-Meso, a mesothelioma clinical trial sponsored by Boehringer Ingelheim, at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
LUME-Meso is a randomized, double-blind, placebo-controlled trial evaluating […]


BREAKING NEWS FROM ASCO: Promising Results Released from Mesothelioma Clinical Trial

This morning, Arnaud Scherpereel, MD, PhD, head of the Pulmonary and Thoracic Oncology Department at the University Hospital of Lille in France, presented the results of the IFCT-1501 MAPS-2 clinical trial at the American Society of Clinical Oncology (ASCO) Annual Meeting. The study was sponsored by the French Cooperative Thoracic Intergroup (IFCT) with drugs and […]